Need to increase the text size?
Prosensa, a Dutch company described as "one of the most promising emerging European biopharmaceutical companies", focuses on research into therapeutics for rare diseases with unmet medical needs. It recently announced €940,000 funding from the Dutch government to support further development of compounds for the treatment of Myotonic Dystrophy type 1 (DM1).
Encouraging news of the willingness of 'big business' to invest in such research comes from the announcement that NEA, a large US venture capital group, has agreed to take a €23m stake in Prosensa, signalling its willingness to invest "in truly exceptional innovation" in Europe and elsewhere.
Contact Us
You can get in contact with us by ringing the Helpline on 0115 987 0080, the office on 0115 987 5869 or for our full contact information, Please go to the Contact us Page.
Join MDSG
Join MDSG today - Fill in our Membership Form Download membership form.
MDSG standing order mandate for subscription. Download form here.
Donate
Donate online using Just Giving.Click on logo.
Donate by text to MDSG02(space) + amount to 70070.
Latest News & Events
© Myotonic Dystrophy Support Group
Registered Charity No. 1134499